Infection with hepatitis C virus (HCV) and HIV frequently complicate stimulant use in the United States. Our preliminary data implicate stimulants and both viruses as causes of neurocognitive impairment. Distinguishing the causes of impairment is essential for medical diagnosis and therapy of all these conditions. In particular, impairment may interfere with abstinence and medical adherence in recovering drug users. For these reasons, we plan to study the effects of drug use, HCV, and HIV on neuropsychological performance, cerebral metabolites, and immune activation. We recently screened subjects enrolled in our NIDA-sponsored Program Project """"""""NeuroAIDS: Effects of Methamphetamine"""""""" for evidence of HCV infection. This preliminary study demonstrated that individuals who were infected with HCV were more neurocognitively impaired than those who were not. In particular, those with HCV-HIV co-infection performed the worst. However, the analysis could not distinguish whether these impairments were attributable to HCV infection or drug use because of sample limitations. The proposed study will be our first step in making this distinction. The primary objectives of the study are 1) to distinguish the effects of drug use, HCV infection, and HIV infection on neuropsychological performance, cerebral metabolism, and immune activation and 2) to evaluate the cerebral metabolic, viral, and other biological correlates of neurocognitive impairment in HCV-infected study participants. We propose a cross-sectional study of 192 participants, stratified in a factorial design by HCV infection, HIV infection, and drug use. We hypothesize that cognitive performance will incrementally worsen based on the number of these risk factors present. Through modeling, we will estimate the individual contribution of each of these conditions. This multidisciplinary study will use four primary assessments: standardized neuropsychological testing, magnetic resonance spectroscopy, markers of HCV and HIV disease activity, and markers of immune activation in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center, a Center to Support Programs in AIDS Research, will provide scientific and operational support for this project. Using this approach, we will define the neurocognitive complications in drug users attributable to stimulant use, HCV, and HIV, as well as investigate their mechanisms. The findings of this research will be used to evaluate the feasibility of an interventional study, and to assist in its design.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA016015-03
Application #
6763986
Study Section
Special Emphasis Panel (ZDA1-RXL-E (07))
Program Officer
Borek, Nicolette T
Project Start
2002-09-30
Project End
2006-12-31
Budget Start
2004-07-01
Budget End
2006-12-31
Support Year
3
Fiscal Year
2004
Total Cost
$425,650
Indirect Cost
Name
University of California San Diego
Department
Psychiatry
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Bharti, Ajay R; McCutchan, Allen; Deutsch, Reena et al. (2016) Latent Toxoplasma Infection and Higher Toxoplasma gondii Immunoglobulin G Levels Are Associated With Worse Neurocognitive Functioning in HIV-Infected Adults. Clin Infect Dis 63:1655-1660
Harrington, Patrick R; Schnell, Gretja; Letendre, Scott L et al. (2009) Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS 23:907-15
Vigil, Ofilio; Posada, Carolina; Woods, Steven Paul et al. (2008) Impairments in fine-motor coordination and speed of information processing predict declines in everyday functioning in hepatitis C infection. J Clin Exp Neuropsychol 30:805-15
Brew, Bruce James; Letendre, Scott Lee (2008) Biomarkers of HIV related central nervous system disease. Int Rev Psychiatry 20:73-88
Podzamczer, Daniel; King, Martin S; Klein, Cheri E et al. (2007) High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response. HIV Clin Trials 8:193-204
Vigil, Ofilio; Woods, Steven Paul; Moran, Lisa M et al. (2007) Is hepatitis C infection associated with increased risk of depression in persons with methamphetamine dependence? Am J Addict 16:418-23
Cherner, M; Letendre, S; Heaton, R K et al. (2005) Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 64:1343-7
Letendre, Scott L; Cherner, Mariana; Ellis, Ronald J et al. (2005) The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS 19 Suppl 3:S72-8